Ramat-Gan, Israel, July 28, 2026
Galmed Pharmaceuticals Ltd. has announced a significant advancement in the development of Aramchol orally dispersible film (ODF), a brain-penetrating formulation of its investigational SCD1 inhibitor designed for the treatment of Parkinson’s disease (PD). The company reported that the proprietary ODF formulation achieved approximately 150% higher systemic bioavailability and 300% greater central nervous system (CNS) exposure compared with conventional oral administration. In addition to improving drug delivery to the brain, the rapidly dissolving formulation addresses one of the most common clinical challenges faced by Parkinson’s patients—dysphagia, or difficulty swallowing—which affects a large proportion of individuals as the disease progresses. Galmed believes that combining a disease-modifying therapeutic mechanism with an easy-to-administer formulation creates a differentiated approach in a therapeutic area where effective long-term treatment options remain limited and positions the program for future co-development and out-licensing opportunities.
Novel ODF Formulation Improves Brain Drug Delivery
The newly developed Aramchol ODF is designed to dissolve within seconds through buccal and sublingual absorption, eliminating the need to swallow traditional tablets or liquids. This delivery strategy reduces first-pass hepatic metabolism, enabling substantially greater drug exposure within the brain while improving overall systemic absorption. According to Galmed, the formulation demonstrated approximately 150% higher bioavailability and nearly 300% increased CNS exposure compared with conventional oral dosing. The technology has been specifically developed to support patients with Parkinson’s disease, where progressive swallowing difficulties frequently compromise medication adherence and treatment effectiveness. By simplifying administration without requiring water, the ODF formulation has the potential to improve patient convenience, enhance long-term compliance, and optimize therapeutic exposure. These characteristics may offer meaningful clinical advantages for patients requiring chronic neurological treatment while supporting broader adoption if future clinical studies confirm efficacy.
SCD1 Inhibition Targets Disease Progression
Unlike currently approved Parkinson’s therapies that primarily address motor symptoms through dopaminergic replacement, Aramchol targets stearoyl-CoA desaturase 1 (SCD1), an enzyme increasingly recognized as a key regulator of lipid metabolism involved in α-synuclein aggregation, Lewy body formation, and neuronal degeneration. Galmed stated that previous in vitro research demonstrated dose-dependent reduction of α-synuclein aggregation without evidence of toxicity, supporting continued investigation of the SCD1 pathway as a potential disease-modifying strategy. Because Aramchol has already accumulated an established clinical safety profile and demonstrated blood-brain barrier penetration, the company believes it possesses several advantages over earlier investigational approaches. The combination of a well-characterized mechanism of action, enhanced CNS exposure, and patient-friendly delivery may help differentiate Aramchol within the evolving Parkinson’s disease therapeutic landscape.
Advertisement
Program Positioned for Future Development Partnerships
Galmed views the Parkinson’s disease program as an attractive opportunity for strategic partnerships and out-licensing, supported by its differentiated scientific profile and proprietary drug delivery technology. The company believes that the combination of enhanced brain exposure, established human safety experience, rapid ODF administration, and potential disease-modifying activity positions Aramchol to address important unmet medical needs in a global Parkinson’s disease market valued at more than $6 billion. While the therapy remains investigational and additional clinical development will be required, the latest formulation advances strengthen Galmed’s broader strategy of expanding innovative applications for Aramchol beyond its previous therapeutic programs. The announcement also highlights the company’s continued focus on developing novel pharmaceutical technologies capable of improving treatment adherence while advancing therapies for complex neurological disorders where effective long-term disease-modifying options remain limited.
Source: Galmed Pharmaceuticals press release
